Trial Profile
A Phase II, Randomized Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of ZD6474 With the Efficacy of ZD1839 (Iressa) in Subjects With Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Cancer After Failure of First-Line Platinum-Based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment With ZD1839.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2016
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Corporation
- 08 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov record (NCT00059722).
- 08 Apr 2009 Primary outcome amended as reported by ClinicalTrials.gov record (NCT00059722).
- 08 Apr 2009 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov record (NCT00059722).